Last reviewed · How we verify

Propofol + Alfentanil

Region Jönköping County · FDA-approved active Small molecule

Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through synergistic central nervous system depression.

Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through synergistic central nervous system depression. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units.

At a glance

Generic namePropofol + Alfentanil
SponsorRegion Jönköping County
Drug classIntravenous anesthetic combination (hypnotic + opioid)
TargetGABA-A receptor (propofol); mu-opioid receptor (alfentanil)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol is an intravenous hypnotic agent that enhances GABAergic inhibitory neurotransmission in the central nervous system, inducing unconsciousness. Alfentanil is a potent synthetic opioid agonist at mu-opioid receptors that provides analgesia and enhances sedation. The combination is used for balanced anesthesia, with propofol providing hypnosis and alfentanil providing analgesia and additional sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: